Lifetime risk of MCI increases with amyloid PET severity, with male APOE ε4 carriers showing a 76.75% risk at centiloid 100 (ref: Jack doi.org/10.1016/S1474-4422(25)00350-3/)
Plasma p-tau217 effectively distinguishes cognitively stable individuals with Down syndrome from those with AD dementia, achieving an AUC of 0.96 (ref: Huber doi.org/10.1038/s41467-025-65882-x/)
Lecanemab activates microglial functions to reduce amyloid pathology, highlighting the importance of immunotherapy in AD treatment (ref: Albertini doi.org/10.1038/s41593-025-02125-8/)
Switching from APOE ε4 to ε2 allele in mice improves metabolic signatures and cognitive performance, indicating potential for genetic interventions (ref: Golden doi.org/10.1038/s41593-025-02094-y/)
Higher physical activity is associated with slower cognitive decline in individuals with elevated amyloid levels (ref: Yau doi.org/10.1038/s41591-025-03955-6/)
The tau biomarker cascade progresses more rapidly in Down syndrome, with earlier positivity for beta-amyloid and tau biomarkers (ref: Zammit doi.org/10.1093/brain/)
CCKBR-Gs and -Gq signaling are beneficial for Alzheimer's disease treatment, suggesting targeted receptor pathways could enhance outcomes (ref: Wang doi.org/10.1016/j.cell.2025.10.034/)
Genetic analysis of delirium identifies APOE as a significant risk factor, independent of dementia (ref: Raptis doi.org/10.1038/s43587-025-01018-6/)